Guidant/Lilly ReoPro marketing alliance will provide support to interventional cardiologists for PTCA.
GUIDANT/LILLY MARKETING ALLIANCE FOR CENTOCOR's REOPRO will provide customer education to interventional cardiology clinicians in support of Lilly's Feb. 9 launch of Centocor's percutaneous transluminal coronary angioplasty adjunct ReoPro (c7E3, abciximab), Guidant announced March 20. Under terms of the agreement, Guidant's Advanced Cardiovascular Systems "will support Lilly's 67 dedicated cardiovascular representatives" during the ReoPro launch via ACS Clinical Application Consultants. ReoPro was approved Dec. 22 as an adjunctive therapy to prevent ischemic complications in PTCA patients at high risk for abrupt vascular closure following surgery ("The Pink Sheet" Jan. 2, p. 16).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth